Guggenheim raised the firm’s price target on Roivant Sciences (ROIV) to $28 from $25 and keeps a Buy rating on the shares. The firm has increased its valuation for brepocitinib in dermatomyositis to $9 from $6 per share to reflect its rare disease-pricing and also made a slight adjustment of IMVT-1402 valuation across multiple indications, the analyst tells investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ROIV:
- Roivant Sciences price target raised to $32 from $29 at Leerink
- Roivant Sciences: Promising Future with Strong Pipeline and Financial Stability
- Roivant Sciences: Promising Outlook with Phase 3 Success and Robust Pipeline Drives Buy Rating
- Roivant Sciences price target raised to $26 from $23 at H.C. Wainwright
- JPMorgan extends Roivant top pick status, adds to Analyst Focus List